Glycoconj J. 2021 Aug;38(4):437-446. doi: 10.1007/s10719-021-09999-3. Epub 2021 Apr 14.

On the use of adenovirus dodecahedron as a carrier for glycoconjugate vaccines.

Glycoconjugate journal

Maruthi Prasanna, Malgorzata Podsiadla-Bialoskorska, Damian Mielecki, Nicolas Ruffier, Amina Fateh, Annie Lambert, Mathieu Fanuel, Emilie Camberlein, Ewa Szolajska, Cyrille Grandjean

PMID: 33852106 DOI: 10.1007/s10719-021-09999-3

Abstract

Virus-Like Particles (VLPs) have been used as immunogenic molecules in numerous recombinant vaccines. VLPs can also serve as vaccine platform to exogenous antigens, usually peptides incorporated within the protein sequences which compose the VLPs or conjugated to them. We herein described the conjugation of a synthetic tetrasaccharide mimicking the Streptococcus pneumoniae serotype 14 capsular polysaccharide to recombinant adenoviral type 3 dodecahedron, formed by the self-assembling of twelve penton bases and investigated the induced immune response when administered subcutaneously (s.c.). Whether formulated in the form of a dodecahedron or disassembled, the glycoconjugate induced an anti-protein response after two and three immunizations equivalent to that observed when the native dodecahedron was administered. On the other hand, the glycoconjugate induced a weak anti-IgM response which diminishes after two doses but no IgM-to-IgG switch was observed in mice against the serotype 14 capsular polysaccharide. In definitive, the whole conjugation process preserved both particulate nature and immunogenicity of the adenoviral dodecahedron. Further studies are needed to fully exploit adenoviral dodecahedron potential in terms of plasticity towards sequence engineering and of its capacity to stimulate the immune system via the intranasal route of administration as well as to shift the response to the carbohydrate antigen by playing both with the carbohydrate to protein ratio and the length of the synthetic carbohydrate antigen.

Keywords: Adenovirus dodecahedron; Carbohydrate antigen; Glycoconjugate vaccine; Streptococcus pneumoniae; Virus-like particle

References

1. Heidelberger, M., Avery, O.T.: The soluble specific substance of pneumococcus. J. Exp. Med. 38(1), 73–79 (1923). https://doi.org/10.1084/jem.38.1.73 - PubMed
2. Rappuoli, R.: Glycoconjugate vaccines: Principles and mechanisms. Sci. Transl. Med. 10(456), 29 (2018). https://doi.org/10.1126/scitranslmed.aat4615 - PubMed
3. Sun, X., Stefanetti, G., Berti, F., Kasper, D.L.: Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines. Proc. Natl. Acad. Sci. U S A. 116(1), 193–198 (2019). https://doi.org/10.1073/pnas.1816401115 - PubMed
4. Bröker, M., Berti, F., Schneider, J., Vojtek, I.: Polysaccharide conjugate vaccine protein carriers as a “neglected valency” - Potential and limitations. Vaccine. 35(25), 3286–3294 (2017). https://doi.org/10.1016/j.vaccine.2017.04.078 - PubMed
5. Micoli, F., Adamo, R., Costantino, P.: Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends. Molecules. 23(6), (2018). https://doi.org/10.3390/molecules23061451 - PubMed
6. Pinto, V.B., Burden, R., Wagner, A., Moran, E.E., Lee, C.-H.: The development of an experimental multiple serogroups vaccine for Neisseria meningitidis. PLoS One. 8(11), e79304 (2013). https://doi.org/10.1371/journal.pone.0079304 - PubMed
7. Grandjean, C., Wade, T.K., Ropartz, D., Ernst, L., Wade, W.F.: Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies. Pathog. Dis. 67(2), 136–158 (2013). https://doi.org/10.1111/2049-632X.12022 - PubMed
8. Woodruff, M.C., Kim, E.H., Luo, W., Pulendran, B.: B Cell Competition for Restricted T Cell Help Suppresses Rare-Epitope Responses. Cell. Rep. 25(2), 321–327.e3 (2018). https://doi.org/10.1016/j.celrep.2018.09.029 - PubMed
9. Pillot, A., Defontaine, A., Fateh, A., Lambert, A., Prasanna, M., Fanuel, M., Pipelier, M., Csaba, N., Violo, T., Camberlein, E., Grandjean, C.: Site-specific conjugation for fully controlled Glycoconjugate vaccine preparation. Front Chem. 7, 726 (2019). https://doi.org/10.3389/fchem.2019.00726 - PubMed
10. Gause, K.T., Wheatley, A.K., Cui, J., Yan, Y., Kent, S.J., Caruso, F.: Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery. ACS Nano. 11(1), 54–68 (2017). https://doi.org/10.1021/acsnano.6b07343 - PubMed
11. Cimica, V., Galarza, J.M.: Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin. Immunol. 183, 99–108 (2017). https://doi.org/10.1016/j.clim.2017.08.004 - PubMed
12. Yan, D., Wei, Y.-Q., Guo, H.-C., Sun, S.-Q.: The application of virus-like particles as vaccines and biological vehicles. Appl. Microbiol. Biotechnol. 99(24), 10415–10432 (2015). https://doi.org/10.1007/s00253-015-7000-8 - PubMed
13. Marcandalli, J., et al.: Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. Cell. 176(6), 1420–1431.e17 (2019). https://doi.org/10.1016/j.cell.2019.01.046 - PubMed
14. Powell, A.E., Zhang, K., Sanyal, M., Tang, S., Weidenbacher, P.A., Li, S., Pham, T.D., Pak, J.E., Chiu, W., Kim, P.S.: A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. ACS Cent. Sci. 7(1), 183–199 (2021). https://doi.org/10.1021/acscentsci.0c01405 - PubMed
15. Sungsuwan, S., Wu, X., Huang, X.: Evaluation of virus-like particle-based tumor-associated carbohydrate Immunogen in a mouse tumor model. Methods Enzymol. 597, 359–376 (2017). https://doi.org/10.1016/bs.mie.2017.06.030 - PubMed
16. Astronomo, R.D., et al.: Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem. Biol. 17(4), 357–370 (2010). https://doi.org/10.1016/j.chembiol.2010.03.012 - PubMed
17. Polonskaya, Z., et al.: T cells control the generation of nanomolar-affinity anti-glycan antibodies. J. Clin. Invest. 127(4), 1491–1504 (2017). https://doi.org/10.1172/JCI91192 - PubMed
18. Fender, P., Ruigrok, R.W., Gout, E., Buffet, S., Chroboczek, J.: Adenovirus dodecahedron, a new vector for human gene transfer. Nat Biotechnol. 15(1), 52–56 (1997). https://doi.org/10.1038/nbt0197-52 - PubMed
19. Vivès, R.R., Lortat-Jacob, H., Chroboczek, J., Fender, P.: Heparan sulfate proteoglycan mediates the selective attachment and internalization of serotype 3 human adenovirus dodecahedron. Virology. 321(2), 332–340 (2004). https://doi.org/10.1016/j.virol.2004.01.015 - PubMed
20. Fender, P., Schoehn, G., Perron-Sierra, F., Tucker, G.C., Lortat-Jacob, H.: Adenovirus dodecahedron cell attachment and entry are mediated by heparan sulfate and integrins and vary along the cell cycle. Virology. 371(1), 155–164 (2008). https://doi.org/10.1016/j.virol.2007.09.026 - PubMed
21. Naskalska, A., Szolajska, E., Andreev, I., Podsiadla, M., Chroboczek, J.: Towards a novel influenza vaccine: engineering of hemagglutinin on a platform of adenovirus dodecahedron. BMC Biotechnol. 13, 50 (2013). https://doi.org/10.1186/1472-6750-13-50 - PubMed
22. Szurgot, I., et al.: Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform. Vaccine. 31(40), 4338–4346 (2013). https://doi.org/10.1016/j.vaccine.2013.07.021 - PubMed
23. Vragniau, C., Bufton, J. C., Garzoni, F., Stermann, E., Rabi, F., Terrat, C., Guidetti, M., Josserand, V., Williams, M., Woods, C.J., Viedma, G., Bates, P., Verrier, B., Chaperot, L., Schaffitzel, C., Berger, I., Fender, P. Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display. Sci. Adv. 5(9), eaaw2853 (2019).  https://doi.org/10.1126/sciadv.aaw2853 - PubMed
24. Szurgot, I., Jedynak, M., Podsiadla-Bialoskorska, M., Piwowarski, J., Szolajska, E., Chroboczek, J.: Adenovirus Dodecahedron, a VLP, Can be Purified by Size Exclusion Chromatography Instead of Time-Consuming Sucrose Density Gradient Centrifugation. Mol. Biotechnol. 57(6), 565–573 (2015). https://doi.org/10.1007/s12033-015-9850-9 - PubMed
25. Prasanna, M., et al.: Semisynthetic glycoconjugate based on dual role protein/PsaA as a pneumococcal vaccine. Eur. J. Pharm. Sci. 129, 31–41 (2019). https://doi.org/10.1016/j.ejps.2018.12.013 - PubMed
26. Herbert, D., Phipps, P. J., Strange, R. E., Chapter III Chemical Analysis of Microbial Cells. In: Methods in Microbiology, 5, J. R. Norris, D. W. Ribbons, Éd. Academic Press, 209–344 (1971).  https://doi.org/10.1016/S0580-9517(08)70641-X - PubMed
27. Grandjean, C., Boutonnier, A., Dassy, B., Fournier, J.-M., Mulard, L.A.: Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba. Glycoconj J. 26(1), 41–55 (2009). https://doi.org/10.1007/s10719-008-9160-6 - PubMed
28. Fuschiotti, P., et al.: Structure of the dodecahedral penton particle from human adenovirus type 3. J. Mol. Biol. 356(2), 510–520 (2006). https://doi.org/10.1016/j.jmb.2005.11.048 - PubMed
29. Safari, D., et al.: Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Infect. Immun. 76(10), 4615–4623 (2008). https://doi.org/10.1128/IAI.00472-08 - PubMed
30. Kurbatova, E.A., Akhmatova, N.K., Akhmatova, E.A., Egorova, N.B., Yastrebova, N.E., Sukhova, E.V., Yashunsky, D.V., Tsvetkov, Y.E., Gening, M.L., Nifantiev, N.E.: Neoglycoconjugate of Tetrasaccharide representing one repeating unit of the Streptococcus pneumoniae type 14 capsular polysaccharide induces the production of opsonizing IgG1 antibodies and possesses the highest protective activity as compared to Hexa- and Octasaccharide conjugates. Front. Immunol. 8, 659 (2017). https://doi.org/10.3389/fimmu.2017.00659 - PubMed
31. Pozsgay, V., Chu, C., Pannell, L., Wolfe, J., Robbins, J.B., Schneerson, R.: Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. U S A. 96(9), 5194–5197 (1999). https://doi.org/10.1073/pnas.96.9.5194 - PubMed
32. Carboni, F., et al.: Evaluation of Immune Responses to Group B Streptococcus Type III Oligosaccharides Containing a Minimal Protective Epitope. J. Infect. Dis. 221(6), 943–947 (2020). https://doi.org/10.1093/infdis/jiz551 - PubMed
33. Mawas, F., Niggemann, J., Jones, C., Corbel, M.J., Kamerling, J.P., Vliegenthart, J.F.G.: Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197. Infect. Immun. 70(9), 5107–5114 (2002). https://doi.org/10.1128/iai.70.9.5107-5114.2002 - PubMed
34. Milhomme, O., et al.: Synthesis and immunochemical evaluation of a non-methylated disaccharide analogue of the anthrax tetrasaccharide. Org. Biomol. Chem. 10(42), 8524–8532 (2012). https://doi.org/10.1039/c2ob26131f - PubMed
35. Khurana, J.M., Gogia, A.: Synthetically Useful Reactions with Nickel Boride. a Review. Org. Preparations Proced. Int. 29(1), 1–32 (1997). https://doi.org/10.1080/00304949709355171 - PubMed
36. Pettersen, E.F., et al.: UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605–1612 (2004). https://doi.org/10.1002/jcc.20084 - PubMed
37. Szolajska, E., et al.: The structural basis for the integrity of adenovirus Ad3 dodecahedron. PLoS One. 7(9), e46075 (2012). https://doi.org/10.1371/journal.pone.0046075 - PubMed
38. Wang, X., et al.: Immune protection efficacy of FAdV-4 surface proteins fiber-1, fiber-2, hexon and penton base. Virus Res. 245, 1–6 (2018). https://doi.org/10.1016/j.virusres.2017.12.003 - PubMed
39. Bal, H.P., Chroboczek, J., Schoehn, G., Ruigrok, R.W., Dewhurst, S.: Adenovirus type 7 penton purification of soluble pentamers from Escherichia coli and development of an integrin-dependent gene delivery system. Eur J Biochem. 267(19), 6074–6081 (2000). https://doi.org/10.1046/j.1432-1327.2000.01684.x - PubMed
40. « Default of the coating can be ruled out since a response has been observed for positive controls - positive sera from previous immunizations - which are added in every tested ELISA plate » - PubMed
41. Peeters, C.C., Tenbergen-Meekes, A.M., Poolman, J.T., Zegers, B.J., Rijkers, G.T.: Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide--protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine. 10(12), 833–840 (1992). https://doi.org/10.1016/0264-410x(92)90046-m - PubMed
42. Rodriguez, M.E., et al.: Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Vaccine. 16(20), 1941–1949 (1998). https://doi.org/10.1016/s0264-410x(98)00129-7 - PubMed
43. Ma, Z., Zhang, H., Wang, P.G., Liu, X.-W., Chen, M.: Peptide adjacent to glycosylation sites impacts immunogenicity of glycoconjugate vaccine. Oncotarget. 9(1), 75–82 (2018). https://doi.org/10.18632/oncotarget.19944 - PubMed
44. Pecetta, S., et al.: Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation. Vaccine. 33(2), 314–320 (2015). https://doi.org/10.1016/j.vaccine.2014.11.026 - PubMed
45. Vinuesa, C.G., Linterman, M.A., Yu, D., MacLennan, I.C.M.: Follicular Helper T Cells. Annu. Rev. Immunol. 34, 335–368 (2016). https://doi.org/10.1146/annurev-immunol-041015-055605 - PubMed
46. Sterrett, S., et al.: Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals. Vaccine. 38(7), 1778–1786 (2020). https://doi.org/10.1016/j.vaccine.2019.12.023 - PubMed
47. Hong, S., et al.: B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4+ T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen. Immunity. 49(4), 695–708.e4 (2018). https://doi.org/10.1016/j.immuni.2018.08.012 - PubMed

Publication Types

• Journal Article